MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Category Archives: Biphasic or Mixed

Combination of epithilioid and sarcomatoid mesothelioma types. Approximately 20-35% of cases are classified as mixed or biphasic mesothelioma.

National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study

The Annals of Thoracic Surgery 2017 December [Epub ahead of print] [Link] Saddoughi SA, Abdelsattar ZM, Blackmon SH Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) remains an aggressive malignancy that is difficult to cure. However, the treatment paradigm of MPM has evolved, and the national practice patterns are unknown. This study examined the national trends in […]

Comments Off on National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study

Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience

Comments Off on Diaphragm and lung-preserving surgery with hyperthermic chemotherapy for malignant pleural mesothelioma: A 10-year experience

Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma

Oncoimmunology 2017 July [Link] Terra SBSP, Mansfield AS, Dong H, Peikert T, Roden AC Abstract Background: Programmed Cell Death 1-Ligand 1 (PD-L1) and Programmed Death Protein 1 (PD-1) blocking antibodies are promising immunotherapies for malignancies. We have previously shown PD-L1 expression in 40% of malignant mesothelioma (MM); however, the temporal and spatial heterogeneity of its […]

Comments Off on Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma

PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma

Asia-Pacific Journal of Clinical Oncology 2017 November [Epub ahead of print] [Link] Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S Abstract AIM: There is currently a need to identify prognostic biomarkers to assist in a risk adopted approach in treatment of malignant pleural mesothelioma (MPM). Expression of programmed death ligand 1 (PD-L1) has […]

Comments Off on PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma

Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application

Chinese Journal of Pathology 2017 October [Link] Guo ZY, Sun WY, Michele Y, Zhang JL, Hu D, Su HN, Yang WM, Mao W Abstract Objective: To investigate the expression of BRCA-associated protein 1 (BAP1) in malignant mesothelioma, non-small cell lung cancer and carcinosarcoma, and its application in the differential diagnosis. Methods: Twenty-two cases of malignant […]

Comments Off on Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application

Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma

Comments Off on Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Journal of Clinical Oncology 2017 September 11 [Epub ahead of print] [Link] Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G Abstract Purpose LUME-Meso is a phase […]

Comments Off on Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

Current Cancer Drug Targets 2017 June 23 [Epub ahead of print] [Link] Zanellato I, Colangelo D, Osella D Abstract Malignant pleural mesothelioma (MPM) is an asbestos-associated tumor with poor prognosis and few therapeutic options. JQ1, a selective antagonist of BRD4, modulates transcription of oncogenes, including MPM chemoresistance-associated c-Myc and Fra-1. We investigated if JQ1 could […]

Comments Off on JQ1, a BET inhibitor, synergizes with cisplatin and induces apoptosis in highly chemoresistant malignant pleural mesothelioma cells

Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists

Oncotarget 2017 May 11 [Epub ahead of print] [Link] Urso L, Cavallari I, Silic-Benussi M, Biasini L, Zago G, Calabrese F, Conte PF, Ciminale V, Pasello G Abstract Malignant Pleural Mesothelioma (MPM) is a chemoresistant tumor characterized by low rate of p53 mutation and upregulation of Murine Double Minute 2 (MDM2), suggesting that it may […]

Comments Off on Synergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists

Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.

British Journal of Cancer 2017 March 14 [Epub 2017 February 14] [Link] Muruganandan S, Alfonso H, Franklin P, Shilkin K, Segal A, Olsen N, Reid A, de Klerk N, Musk AB, Brims F Abstract BACKGROUND: Survival with the epithelioid subtype of malignant mesothelioma (MM) is longer than the biphasic or sarcomatoid subtypes. There is concern […]

Comments Off on Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.